Aurobindo Pharma receives EIR for Hyderabad manufacturing facility

19 Feb 2020 Evaluate

Aurobindo Pharma has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status from the US Food and Drug Administration (USFDA) for its Unit IV, a general injectable formulation manufacturing facility situated at Pashamylaram, Hyderabad. The USFDA had inspected company's Unit IV from November 4, 2019 to November 13, 2019.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1157.25 -9.95 (-0.85%)
20-Jan-2026 11:15 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1653.90
Dr. Reddys Lab 1170.15
Cipla 1390.00
Zydus Lifesciences 879.85
Lupin 2165.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×